Co-DiagnosticsCODX
About: Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
Employees: 132
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
38% more call options, than puts
Call options by funds: $11K | Put options by funds: $8K
3% more funds holding
Funds holding: 37 [Q4 2024] → 38 (+1) [Q1 2025]
0.51% less ownership
Funds ownership: 17.92% [Q4 2024] → 17.41% (-0.51%) [Q1 2025]
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
58% less capital invested
Capital invested by funds: $4.3M [Q4 2024] → $1.81M (-$2.49M) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
D. Boral Capital Jason Kolbert 22% 1-year accuracy 89 / 402 met price target | 3,233%upside $10 | Buy Initiated | 28 Apr 2025 |
HC Wainwright & Co. Yi Chen 34% 1-year accuracy 55 / 160 met price target | 233%upside $1 | Neutral Maintained | 28 Mar 2025 |
Financial journalist opinion
Based on 5 articles about CODX published over the past 30 days
